Design and Optimization of Novel Pyrimidine-Morpholine Hybrids Through Computational Approaches for SRC Kinase
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bangalore, Karnataka, India.
Drug Research
|April 17, 2025
Summary
Novel pyrimidine-morpholine hybrids show potential as SRC kinase inhibitors for breast cancer. These compounds exhibit promising interactions and favorable ADMET properties, suggesting their utility in developing new cancer therapies.
Area of Science:
- Oncology
- Medicinal Chemistry
- Biochemistry
Background:
- Src kinase is crucial for tumor survival, proliferation, and metastasis in various cancers.
- Targeting Src kinase offers a therapeutic strategy for Src-dependent malignancies.
- Nitrogen-containing heterocyclic compounds are known for diverse biological activities.
Purpose of the Study:
- To design and evaluate novel pyrimidine-morpholine hybrids as potential SRC kinase inhibitors.
- To assess the binding interactions and drug-likeness of these novel compounds.
- To explore their therapeutic potential in breast cancer research.
Main Methods:
- Synthesis of pyrimidine-morpholine hybrids.
- Shape similarity analysis with Dasatinib using Tanimoto coefficient.
- Molecular docking studies with human tyrosine kinase (PDB ID: 2SRC) using AutoDock Vina.
- Analysis of binding affinities and ADMET properties.
- Molecular simulation studies for stability assessment.
Main Results:
- Designed pyrimidine-morpholine hybrids demonstrated shape similarity to Dasatinib.
- Docking studies revealed promising interactions of hybrid molecules with 2SRC.
- Compounds exhibited favorable predicted ADMET properties.
- Molecular simulations confirmed the stability of docked complexes.
Conclusions:
- The novel pyrimidine hybrids are potential SRC kinase inhibitors.
- These compounds show promise as lead molecules for developing novel druggable moieties.
- Further research in breast cancer is warranted for these pyrimidine hybrids.
